n their recent Endocrine Society position statement on the measurement of estradiol, Rosner et al (1) provide a good overview of the current status of estradiol assays in the context of their clinical and research applications. The position statement includes both published data and the expert opinions of the authors, and it is long overdue because estradiol assay methods that lack accuracy and precision are being used in many clinical and research settings (2, 3). Problems of inaccuracy are particularly found when measuring the low estradiol levels commonly seen in prepubertal children, postmenopausal women, and men, as well as in patients treated with aromatase inhibitors. The position statement outlines the many challenges associated with standardizing estradiol measurements using mass spectrometry assay methodology. The purpose of the present commentary is to point out: 1) the relevant populations in which estradiol measurements are critical; and 2) the problematic ranges of these measurements.
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Range of Estradiol Measurements
A very wide range of estradiol levels are seen in clinical and research settings (Table 1) . Physiological estradiol levels in prepubertal children, adolescents, and adult women (premenopausal, pregnant, and postmenopausal) and men encompass a range of approximately 1-20 000 pg/mL. This range also includes estradiol levels obtained in breast cancer patients treated with aromatase inhibitors, in postmenopausal women treated with estrogen, and in patients undergoing ovarian stimulation treatment. The range can be extended at the lower end to Ͻ1 pg/mL in patients treated with aromatase inhibitors. Thus, estradiol assays employed by clinical and research laboratories are required to be accurate and precise across several orders of concentration.
Estradiol Measurements in Relevant Populations
It is obvious from the position statement that standardizing estradiol assays to encompass such a wide range of estradiol levels will be a formidable task and could take years to accomplish, although the difficulties already encountered and overcome in standardizing the T assay should provide useful information. Our recommended approach is to focus on standardizing assays that measure estradiol levels in the range of l-1000 pg/mL. This range would include the very low estradiol levels (Ͻ20 pg/mL) found in prepubertal children, postmenopausal women, and patients treated with aromatase inhibitors. Also included in that range would be the estradiol levels found in adolescent boys and in men (Ͻ40 pg/mL); in premenopausal women during the follicular, periovulatory, and luteal phases of the menstrual cycle (30 -800 pg/mL); and in postmenopausal women treated with estrogenic preparations, for example, conjugated equine estrogens or micronized estradiol (20 -100 pg/mL).
At the present time, it is not necessary to standardize assays that measure estradiol levels Ͼ1000 pg/mL, which are found in pregnancy and in premenopausal women undergoing fertility treatments involving controlled ovarian stimulation. Although circulating levels of estradiol increase dramatically during the second and third trimesters of pregnancy and reach levels as high as 20 ng/mL (4), estradiol is not a good marker of fetal well-being because its androgenic precursor dehydroepiandrosterone sulfate is derived equally from the maternal and fetal compartments (5). Instead, estriol has been used as the marker because its androgenic precursor (16␣-hydroxy dehydroepiandrosterone sulfate) is derived predominantly from the fetus (5) . By contrast, measurement of estradiol plays an important role in monitoring response during ovarian stimulation in women with infertility.
Owing to the very high estradiol levels (up to 10 ng/mL) achieved during ovarian stimulation treatment, estradiol is measured predominantly by direct immunoassays on automated platforms, which are now frequently located in doctors' offices. Although estradiol levels are overestimated by these direct assays owing to cross-reaction with high levels of estradiol metabolites, for example, estrone sulfate, clinicians are aided in their interpretation of estradiol levels by concurrent ultrasound monitoring of ovarian follicular development. Moreover, fertility clinics require rapid, cost-effective, same-day results to facilitate clinical management of their patients; therefore, sending the samples away for mass spectrometry assessment would be inconvenient and too costly. Furthermore, in addition to measuring estradiol, immunoassay-based instruments are also capable of measuring reproductive proteins, eg, FSH and human chorionic gonadotropin, which are essential for monitoring patients undergoing ovarian stimulation treatment.
The increasing permeation of mass spectrometry assays throughout the large diagnostic clinical laboratories means that in the near future mass spectrometry-based measurements will probably be available on the same day to clinicians. The advent of affordable, accessible, and accurate mass spectrometry-based assays for use in physicians' offices and smaller laboratories will no doubt present challenges at first. However, it is becoming clear that this is the inevitable direction in which vendors of mass spectrometry instruments are moving. The first fully integrated diagnostic instruments will most likely be targeted at reference labs or larger hospital laboratories.
Over time they will undoubtedly morph into smaller, simpler, and less expensive instruments destined for the smaller practice laboratories and physicians' offices. Some of the challenges that the vendors will face will depend on the type of instrument involved, but it will be important for all of these instruments to be user-friendly, fully integrated, and comparable to the currently used immunoassay platforms in terms of expense and skill set. It will also be important for the instrument vendors to do as much as possible in supplying fully validated clinical mass spectrometry assays. This is essential for labs that don't have access to research and development personnel.
Problematic Ranges of Estradiol Measurements
An important and difficult challenge identified in the position statement is the standardization of estradiol measurements at the very low concentrations (Ͻ30 pg/mL) found in prepubertal girls and boys and in postmenopausal women, as well as the extremely low concentrations that can be achieved in patients undergoing treatment with aromatase inhibitors. Standardizing estradiol measurements is especially important for patients with breast cancer receiving aromatase inhibitors because their serum samples are often sent to diagnostic testing laboratories that use direct estradiol immunoassays-assays in which estradiol is not purified before its quantitation (6) . Antibodies in direct immunoassays often cross-react with aromatase inhibitors and their metabolites and affect the test results, which is especially true of exemestane (7) . The falsely high results from such assays could affect the treatment outcome and safety of patients.
The validity of very low estradiol measurements is questionable, even in the research setting when these measurements are obtained by conventional RIA methods in which estradiol first undergoes one or two purification steps. These assays are often used in studies that determine the suppression of estradiol levels by aromatase inhibitors. Notable deficiencies in some of these assay methods include the following: extrapolation of estradiol concentrations below the lowest point on the standard curve; use of an insufficient number of estradiol concentrations at the low end to generate an accurate standard curve; lack of a chromatographic step to separate potential unconjugated cross-reacting compounds (the aromatase inhibitor and its metabolites, and estradiol metabolites); and addition of too much mass of estradiol to each sample when 3 H-estradiol is used as the internal standard to follow procedural losses. Also, the claimed estradiol assay sensitivity in some studies is Ͻ1 pg/mL, yet no information is given regarding how the sensitivity was determined. Such discrepancies have become increasingly clear with the adoption of analysis using mass spectrometry.
Reference Intervals
Another major challenge discussed in the position statement is the requirement for estradiol reference intervals derived from well-characterized, adequately sized populations using standardized procedures, such as those formulated by the Clinical and Laboratory Standards Institute. A particular challenge will be the establishment of reference ranges in a sufficient number of postmenopausal women by age groups, stage of postmenopause, and type of menopause (natural vs surgical). Because adipose tissue is the predominant source of estradiol in postmenopausal women, the estradiol reference ranges will have to be adjusted for level of obesity. Serum estradiol levels in postmenopausal women are positively associated with body mass index (8) . Of note, the interaction of age and body mass index can also affect estradiol concentrations in estrogen-treated postmenopausal women (8) . Taking these factors into account, accurate estradiol reference ranges for postmenopausal women can help guide individualized hormone replacement therapy to ensure that levels are kept within a physiological range.
Conclusion
Ultimately, meeting the challenges specified in The Endocrine Society position statement will have a major impact on the diagnosis and treatment of endocrine-related disorders and disease. The position statement should motivate those involved with estradiol assays to strive for accuracy and precision, which is in the best interest of the patient.
